Low-dose Ginsenosides Supplementation Suppress The Muscle Damage And Oxidative Stress After Single Bout Resistance Exercise

2010 ◽  
Vol 42 ◽  
pp. 789
Author(s):  
Shu-Yun Lu ◽  
Hsiu-Hua Chen ◽  
Mei-Chih Chen ◽  
Li-Yen Tsao ◽  
Anthony Haddrick ◽  
...  
2018 ◽  
Vol 14 (2) ◽  
pp. 387-392
Author(s):  
Daniel dos Santos Ferreira ◽  
Lydiane Tavares Toscano ◽  
Tayse Guedes Cabral ◽  
Gilberto Santos Cerqueira ◽  
Ana Carla Lima de França ◽  
...  

2021 ◽  
Vol 165 ◽  
pp. 56-57
Author(s):  
Shota Naoe ◽  
Takahiro Kataoka ◽  
Hina Shuto ◽  
Junki Yano ◽  
Tetsuya Nakada ◽  
...  

1970 ◽  
Vol 36 (1) ◽  
pp. 14-19
Author(s):  
Md. Zakirul Islam ◽  
Md. Sayedur Rahman

The study was conducted to evaluate the anti-atherogenic potential of losartan and to assess the effects of hydrochlorothiazide and indapamide on losartan activity in rat. Cholesterol diet (0.5%) for 12 weeks led to significant hyperlipidemia, increased body weight and oxidative stress in erythrocyte. While, losartan, hydrochlorothiazide and indapamide treatment continued for next 12 weeks, losartan showed anti-atherogenic activity reflected by hypolipidemic effect and antioxidant effect in erythrocyte. This activity was abolished by addition of hydrochlorothiazide with losartan but remained unaltered by addition of indapamide with losartan. Atherosclerotic change and oxidative stress were not found in rat aorta, which may be due to short duration and low dose of cholesterol feeding. Hydrochlorothiazide treatment was associated with hypokalemia, which was not present in losartan or indapamide treatment. This study suggests that indapamide might be co-administered with losartan conserving the essential anti-atherogenic potential of losartan.Online: 13 July 2010DOI: http://dx.doi.org/10.3329/bmrcb.v36i1.5447Bangladesh Med Res Counc Bull 2010; 36: 14-19   


2015 ◽  
Vol 47 ◽  
pp. 646
Author(s):  
Kevin Schill ◽  
Alex Altenburger ◽  
Alex Fultz ◽  
Jeovanna Lowe ◽  
Muthu Periasamy ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-22
Author(s):  
Yang Zhang ◽  
Weifang Liu ◽  
Yanqi Zhong ◽  
Qi Li ◽  
Mengying Wu ◽  
...  

NOD-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome-mediated pyroptosis is a crucial event in the preeclamptic pathogenesis, tightly linked with the uteroplacental TLR4/NF-κB signaling. Trophoblastic glycometabolism reprogramming has now been noticed in the preeclampsia pathogenesis, plausibly modulated by the TLR4/NF-κB signaling as well. Intriguingly, cellular pyroptosis and metabolic phenotypes may be inextricably linked and interacted. Metformin (MET), a widely accepted NF-κB signaling inhibitor, may have therapeutic potential in preeclampsia while the underlying mechanisms remain unclear. Herein, we investigated the role of MET on trophoblastic pyroptosis and its relevant metabolism reprogramming. The safety of pharmacologic MET concentration to trophoblasts was verified at first, which had no adverse effects on trophoblastic viability. Pharmacological MET concentration suppressed NLRP3 inflammasome-induced pyroptosis partly through inhibiting the TLR4/NF-κB signaling in preeclamptic trophoblast models induced via low-dose lipopolysaccharide. Besides, MET corrected the glycometabolic reprogramming and oxidative stress partly via suppressing the TLR4/NF-κB signaling and blocking transcription factor NF-κB1 binding on the promoter PFKFB3, a potent glycolytic accelerator. Furthermore, PFKFB3 can also enhance the NF-κB signaling, reduce NLRP3 ubiquitination, and aggravate pyroptosis. However, MET suppressed pyroptosis partly via inhibiting PFKFB3 as well. These results provided that the TLR4/NF-κB/PFKFB3 pathway may be a novel link between metabolism reprogramming and NLRP3 inflammasome-induced pyroptosis in trophoblasts. Further, MET alleviates the NLRP3 inflammasome-induced pyroptosis, which partly relies on the regulation of TLR4/NF-κB/PFKFB3-dependent glycometabolism reprogramming and redox disorders. Hence, our results provide novel insights into the pathogenesis of preeclampsia and propose MET as a potential therapy.


2009 ◽  
Vol 44 (5) ◽  
pp. 487-491 ◽  
Author(s):  
H. Vandenhove ◽  
N. Vanhoudt ◽  
J. Wannijn ◽  
M. Van Hees ◽  
A. Cuypers

2017 ◽  
Vol 36 (1) ◽  
pp. 104-110 ◽  
Author(s):  
Gabriel R. Neto ◽  
Jefferson S. Novaes ◽  
Verônica P. Salerno ◽  
Michel M. Gonçalves ◽  
Gilmário R. Batista ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document